ARC101 in Advanced Solid Tumors

Inclusion Criteria:

• Locally advanced or metastatic solid tumor ovarian, testicular or other Claudin 6+cancers

• Measurable or evaluable disease, per RECIST v1.1

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1

• Adequate organ function

Exclusion Criteria:

• Active CNS involvement

• Malignancy diagnosis other than the disease under study within 2 years prior to thefirst dose of study drug.

• Presence of uncontrolled ascites

• Toxicity related to prior anticancer therapy that has not returned to Grade ≤1 orbaseline levels

• Clinically significant pulmonary compromise

• Active autoimmune disease within 12 months prior to first dose of study drug.

• Female participant who is pregnant, breastfeeding, or plans to become pregnant ormale participant who plans to father a child either while enrolled or within 90 daysafter the final administration of study drug.